SRC and sarcoma: To investigate whether targeting the FAK-Src complex could increase the observed therapeutic responses after single-agent treatment, we investigated the effects of simultaneous defactinib and dasatinib combination treatment on (p)FAK and (p)Src expressions in one representative cell line per sarcoma subtype: JN-DSRCT-1, TC32, Rh30, and RD.